The art of obtaining a high yield of cell-free DNA from urine

Although liquid biopsies offer many advantages over tissue biopsies, they are not yet standard practice. An important reason for the lack of implementation is the unavailability of well standardized techniques and guidelines, especially for pre-analytical conditions which are an important factor causing the current sensitivity issues. To overcome these limitations, we investigated the effect of several pre-analytical conditions on the concentration of cell-free DNA (cfDNA) and cellular genomic DNA (gDNA) contamination. Urine samples from healthy volunteers (HVs) and cancer patients were collected and processed according to specific pre-analytical conditions. Our results show that in samples with a relatively small volume more than 50% of the cfDNA can be found in the first 50 mL of the urine sample. The total DNA concentration increased again when samples were collected more than 3.5 hours apart. Adding preservative to urine samples is recommended to obtain high concentrations of cfDNA. To remove the cellular content, high speed centrifugation protocols as 4,000g 10min or 3,000g 15min are ideal for urine collected in cfDNA Urine Preserve (Streck). Although this study was a pilot study and needs to be confirmed in a larger study population, clear trends in the effect of several pre-analytical conditions were observed.

[1]  M. Tetzlaff,et al.  Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma , 2019, Cancers.

[2]  James J. Lai,et al.  Analytical Comparison of Methods for Extraction of Short Cell-Free DNA from Urine. , 2019, The Journal of molecular diagnostics : JMD.

[3]  Surbhi Jain,et al.  Urine-Based Liquid Biopsy for Nonurological Cancers. , 2019, Genetic testing and molecular biomarkers.

[4]  J. V. van Meerbeeck,et al.  Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol , 2019, Cancers.

[5]  M. Bebawy,et al.  Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. , 2019, Trends in pharmacological sciences.

[6]  P. van Damme,et al.  Human papillomavirus detection in urine: Effect of a first-void urine collection device and timing of collection. , 2019, Journal of virological methods.

[7]  A. Ashare,et al.  Pre-Analytical Handling Conditions and Small RNA Recovery from Urine for miRNA Profiling. , 2018, The Journal of molecular diagnostics : JMD.

[8]  J. V. van Meerbeeck,et al.  A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting , 2018, Cancers.

[9]  G. Kazemier,et al.  A protocol for urine collection and storage prior to DNA methylation analysis , 2018, PloS one.

[10]  M. Tiemann,et al.  Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. , 2018, The Journal of molecular diagnostics : JMD.

[11]  Brooke L. Billman,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Robyn L. Temple-Smolkin,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. , 2018, The Journal of molecular diagnostics : JMD.

[13]  S. Khier,et al.  Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature , 2018, Future science OA.

[14]  B. Sundaram,et al.  Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Reena Philip,et al.  FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation , 2017, The oncologist.

[16]  M. Erlander,et al.  Urine test for EGFR analysis in patients with non-small cell lung cancer. , 2017, Journal of thoracic disease.

[17]  M. Huibers,et al.  Preanalytical blood sample workup for cell‐free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics , 2017, Cancer medicine.

[18]  N. Rosenfeld,et al.  Selecting short DNA fragments in plasma improves detection of circulating tumour DNA , 2017, bioRxiv.

[19]  A. Bardelli,et al.  Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.

[20]  Robyn L. Temple-Smolkin,et al.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. , 2017, Archives of pathology & laboratory medicine.

[21]  Jinming Li,et al.  Clinical applications of urinary cell-free DNA in cancer: current insights and promising future. , 2017, American journal of cancer research.

[22]  P. Pauwels,et al.  A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma. , 2017, The Journal of molecular diagnostics : JMD.

[23]  M. Erlander,et al.  A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Min Seong Kim,et al.  Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma , 2015, Scientific Reports.

[25]  A. Kohlmann,et al.  Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) , 2016, PloS one.

[26]  Jian-Bing Fan,et al.  Accessing Genetic Information with Liquid Biopsies. , 2015, Trends in genetics : TIG.

[27]  P. van Damme,et al.  Urine testing for HPV: rationale for using first void , 2014, BMJ : British Medical Journal.

[28]  M. Ieven,et al.  Optimization of HPV DNA detection in urine by improving collection, storage, and extraction , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[29]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Williams,et al.  A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. , 2013, Clinical biochemistry.

[31]  R. Murthy,et al.  Use of research biopsies in clinical trials: are risks and benefits adequately discussed? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Jiang,et al.  High Resolution Size Analysis of Fetal DNA in the Urine of Pregnant Women by Paired-End Massively Parallel Sequencing , 2012, PloS one.

[33]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[34]  Ana K Stankovic,et al.  Quality improvements in the preanalytical phase: focus on urine specimen workflow. , 2008, Clinics in laboratory medicine.

[35]  S. Syngal,et al.  Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. , 2004, The Journal of molecular diagnostics : JMD.

[36]  Mario Plebani,et al.  Errors in laboratory medicine. , 2002, Clinical chemistry.

[37]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.